0001237899-20-000014.txt : 20200310 0001237899-20-000014.hdr.sgml : 20200310 20200310160539 ACCESSION NUMBER: 0001237899-20-000014 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200309 FILED AS OF DATE: 20200310 DATE AS OF CHANGE: 20200310 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GOLDSTEIN JOSEPH L CENTRAL INDEX KEY: 0001225474 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 20701557 MAIL ADDRESS: STREET 1: DEPT OF PHARMACOLOGY K5 YUVER OF TEXAS STREET 2: 5323 HARRY HINES BLVD CITY: DALLAS STATE: TX ZIP: 75390 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2020-03-09 0 0000872589 REGENERON PHARMACEUTICALS, INC. REGN 0001225474 GOLDSTEIN JOSEPH L 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 1 0 0 0 Common Stock 2020-03-09 4 M 0 2000 33.42 A 11643 D Common Stock 2020-03-09 4 S 0 200 468.14 D 11443 D Common Stock 2020-03-09 4 S 0 100 469.8 D 11343 D Common Stock 2020-03-09 4 S 0 200 470.83 D 11143 D Common Stock 2020-03-09 4 S 0 100 471.34 D 11043 D Common Stock 2020-03-09 4 S 0 73 474.88 D 10970 D Common Stock 2020-03-09 4 S 0 327 475.31 D 10643 D Common Stock 2020-03-09 4 S 0 200 476.16 D 10443 D Common Stock 2020-03-09 4 S 0 500 479.21 D 9943 D Common Stock 2020-03-09 4 S 0 300 482.82 D 9643 D Non-Qualified Stock Option (right to buy) 33.42 2020-03-09 4 M 0 2000 0.0 D 2021-01-03 Common Stock 2000 0 D Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Represents volume-weighted average price of sales of 327 shares of Company stock on March 9, 2020 at prices ranging from $475.19 to $475.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 9, 2020 at each separate price. Represents volume-weighted average price of sales of 200 shares of Company stock on March 9, 2020 at prices ranging from $476.15 to $476.17. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 9, 2020 at each separate price. Represents volume-weighted average price of sales of 500 shares of Company stock on March 9, 2020 at prices ranging from $479.05 to $479.34. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 9, 2020 at each separate price. Represents volume-weighted average price of sales of 300 shares of Company stock on March 9, 2020 at prices ranging from $482.51 to $482.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 9, 2020 at each separate price. The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. /s/**Joseph L. Goldstein 2020-03-09